m6A-centered Disease Response Information
General Information of the Disease (ID: M6ADIS0141)
Name |
COVID-19
|
||||
---|---|---|---|---|---|
ICD |
ICD-11: RA01
|
Full List of Target Gene(s) of This m6A-centered Disease Response
Mammalian target of rapamycin complex 2 (mTORC2)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [1] | |||
Response Summary | Knockdown of RBM15 remarkably suppressed the expression levels of multitarget genes related to programmed cell death and inflammatory response. These findings indicate that RBM15 can serve as a target for the treatment of COVID-19. | |||
Responsed Disease | COVID-19 [ICD-11: RA01] | |||
Target Regulator | RNA-binding motif protein 15 (RBM15) | WRITER | ||
Cell Process | Programmed cell death | |||
Inflammatory response | ||||
In-vitro Model | THP-1 | Childhood acute monocytic leukemia | Homo sapiens | CVCL_0006 |
HuT 78 | T lymphocytic leukemia | Homo sapiens | CVCL_0337 | |
RIG-I-like receptor 1 (RIG-I)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [2] | |||
Response Summary | In SARS-CoV-2 infection, depletion of the host cell m6A methyltransferase METTL3 decreases m6A levels in SARS-CoV-2 and host genes, and m6A reduction in viral RNA increases RIG-I-like receptor 1 (RIG-I) binding and subsequently enhances the downstream innate immune signaling pathway and inflammatory gene expression. | |||
Responsed Disease | COVID-19 [ICD-11: RA01] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Down regulation | |||
Pathway Response | RIG-I-like receptor signaling pathway | hsa04622 | ||
Cell Process | Immune responses | |||
In-vitro Model | Calu-3 | Lung adenocarcinoma | Homo sapiens | CVCL_0609 |
Caco-2 | Colon adenocarcinoma | Homo sapiens | CVCL_0025 | |
HEK293-FT | Normal | Homo sapiens | CVCL_6911 | |
References